nodes	percent_of_prediction	percent_of_DWPC	metapath
Valganciclovir—SLC6A14—mammary gland—breast cancer	0.0341	0.369	CbGeAlD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—PEX14—breast cancer	0.0171	0.0879	CbGpPWpGaD
Valganciclovir—SLC6A14—female reproductive system—breast cancer	0.0141	0.153	CbGeAlD
Valganciclovir—SLC6A14—endocrine gland—breast cancer	0.0119	0.129	CbGeAlD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—SLC4A7—breast cancer	0.00899	0.0461	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—PIM1—breast cancer	0.00565	0.029	CbGpPWpGaD
Valganciclovir—SLC15A2—mammary gland—breast cancer	0.00537	0.0582	CbGeAlD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC4A7—breast cancer	0.00529	0.0272	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A10—breast cancer	0.00521	0.0267	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—CSF1R—breast cancer	0.0048	0.0246	CbGpPWpGaD
Valganciclovir—SLC15A1—epithelium—breast cancer	0.00479	0.0519	CbGeAlD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A7—breast cancer	0.00431	0.0221	CbGpPWpGaD
Valganciclovir—SLC15A1—endometrium—breast cancer	0.00429	0.0465	CbGeAlD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A18—breast cancer	0.00395	0.0203	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A5—breast cancer	0.0038	0.0195	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SLC2A10—breast cancer	0.00375	0.0193	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—ALDH3A1—breast cancer	0.00349	0.0179	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—ABCG2—breast cancer	0.00333	0.0171	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—breast cancer	0.00327	0.0168	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SLC39A7—breast cancer	0.00311	0.016	CbGpPWpGaD
Valganciclovir—SLC15A1—endocrine gland—breast cancer	0.00301	0.0326	CbGeAlD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—breast cancer	0.00282	0.0145	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SLC2A5—breast cancer	0.00274	0.0141	CbGpPWpGaD
Valganciclovir—SLC6A14—Amino acid and oligopeptide SLC transporters—SLC5A5—breast cancer	0.00272	0.014	CbGpPWpGaD
Valganciclovir—SLC15A2—endometrium—breast cancer	0.00268	0.0291	CbGeAlD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC28A1—breast cancer	0.00259	0.0133	CbGpPWpGaD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC4A7—breast cancer	0.0025	0.0129	CbGpPWpGaD
Valganciclovir—SLC15A2—pituitary gland—breast cancer	0.00243	0.0263	CbGeAlD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC2A10—breast cancer	0.00237	0.0121	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC4A7—breast cancer	0.00237	0.0121	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SLC39A6—breast cancer	0.00236	0.0121	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC4A7—breast cancer	0.00232	0.0119	CbGpPWpGaD
Valganciclovir—SLC15A2—female reproductive system—breast cancer	0.00222	0.0241	CbGeAlD
Valganciclovir—SLC15A2—adrenal gland—breast cancer	0.00217	0.0235	CbGeAlD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—breast cancer	0.00214	0.011	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—ABCB1—breast cancer	0.00208	0.0107	CbGpPWpGaD
Valganciclovir—SLC15A2—female gonad—breast cancer	0.00202	0.0219	CbGeAlD
Valganciclovir—SLC6A14—NRF2 pathway—GSTA3—breast cancer	0.002	0.0103	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—breast cancer	0.00197	0.0101	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC39A7—breast cancer	0.00196	0.0101	CbGpPWpGaD
Valganciclovir—SLC15A2—endocrine gland—breast cancer	0.00188	0.0204	CbGeAlD
Valganciclovir—SLC6A14—NRF2 pathway—GSTA4—breast cancer	0.00183	0.00941	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC22A18—breast cancer	0.00179	0.0092	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTA2—breast cancer	0.00179	0.00917	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GPX2—breast cancer	0.00179	0.00917	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC2A5—breast cancer	0.00173	0.00886	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLCO1B1—breast cancer	0.00173	0.00886	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTA1—breast cancer	0.00172	0.00885	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—breast cancer	0.0016	0.00823	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—breast cancer	0.0015	0.00768	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC39A6—breast cancer	0.00149	0.00763	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SLC2A2—breast cancer	0.00142	0.00728	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC28A1—breast cancer	0.00131	0.00675	CbGpPWpGaD
Valganciclovir—SLC15A2—lymph node—breast cancer	0.0013	0.0141	CbGeAlD
Valganciclovir—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC5A5—breast cancer	0.00129	0.00661	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—TGFB2—breast cancer	0.00124	0.00636	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC28A1—breast cancer	0.00122	0.00628	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC2A10—breast cancer	0.0012	0.00617	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC4A7—breast cancer	0.0012	0.00617	CbGpPWpGaD
Valganciclovir—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC5A5—breast cancer	0.0012	0.00614	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SQSTM1—breast cancer	0.00117	0.00601	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SLC5A5—breast cancer	0.00114	0.00584	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC28A1—breast cancer	0.00114	0.00583	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC4A7—breast cancer	0.00112	0.00574	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC2A10—breast cancer	0.00112	0.00574	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SLC2A1—breast cancer	0.0011	0.00564	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—NQO1—breast cancer	0.0011	0.00564	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—breast cancer	0.00108	0.00553	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC2A10—breast cancer	0.00104	0.00533	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC4A7—breast cancer	0.00104	0.00533	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—HSP90AA1—breast cancer	0.00103	0.0053	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—EGR1—breast cancer	0.00102	0.00523	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC39A7—breast cancer	0.000996	0.00511	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—COX11—breast cancer	0.000996	0.00511	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC39A7—breast cancer	0.000927	0.00476	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTP1—breast cancer	0.000916	0.0047	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—TGFBR2—breast cancer	0.000916	0.0047	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC22A18—breast cancer	0.000911	0.00468	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—HMOX1—breast cancer	0.000903	0.00464	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC2A2—breast cancer	0.000894	0.00459	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLCO1B1—breast cancer	0.000877	0.0045	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC2A5—breast cancer	0.000877	0.0045	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC39A7—breast cancer	0.000861	0.00442	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC22A18—breast cancer	0.000848	0.00435	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—HGF—breast cancer	0.000842	0.00432	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTM1—breast cancer	0.000842	0.00432	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—NRG1—breast cancer	0.000826	0.00424	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—breast cancer	0.000824	0.00423	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC2A5—breast cancer	0.000816	0.00419	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLCO1B1—breast cancer	0.000816	0.00419	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC22A18—breast cancer	0.000787	0.00404	CbGpPWpGaD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—breast cancer	0.000759	0.00389	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLCO1B1—breast cancer	0.000758	0.00389	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC2A5—breast cancer	0.000758	0.00389	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC39A6—breast cancer	0.000755	0.00388	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC5A5—breast cancer	0.000717	0.00368	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—breast cancer	0.000704	0.00361	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC39A6—breast cancer	0.000703	0.00361	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC2A1—breast cancer	0.000692	0.00355	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ATP7B—breast cancer	0.000691	0.00354	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC39A6—breast cancer	0.000652	0.00335	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ABCC1—breast cancer	0.000642	0.00329	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC28A1—breast cancer	0.000622	0.00319	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC28A1—breast cancer	0.000577	0.00296	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC2A10—breast cancer	0.000569	0.00292	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC4A7—breast cancer	0.000569	0.00292	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—TUBB3—breast cancer	0.000546	0.0028	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC2A10—breast cancer	0.000528	0.00271	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC4A7—breast cancer	0.000528	0.00271	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—COX11—breast cancer	0.000471	0.00242	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC39A7—breast cancer	0.000471	0.00242	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC2A2—breast cancer	0.000454	0.00233	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ABCG2—breast cancer	0.000445	0.00228	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC39A7—breast cancer	0.000437	0.00224	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—COX11—breast cancer	0.000437	0.00224	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC22A18—breast cancer	0.000431	0.00221	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC2A2—breast cancer	0.000423	0.00217	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC2A5—breast cancer	0.000415	0.00213	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLCO1B1—breast cancer	0.000415	0.00213	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC22A18—breast cancer	0.0004	0.00205	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—TFRC—breast cancer	0.000397	0.00204	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC2A2—breast cancer	0.000392	0.00201	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC2A5—breast cancer	0.000385	0.00198	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLCO1B1—breast cancer	0.000385	0.00198	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—NCOA2—breast cancer	0.000382	0.00196	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC5A5—breast cancer	0.000364	0.00187	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC39A6—breast cancer	0.000357	0.00183	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC2A1—breast cancer	0.000352	0.00181	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—TGFB1—breast cancer	0.000343	0.00176	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—ALB—breast cancer	0.000342	0.00175	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC5A5—breast cancer	0.000339	0.00174	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC39A6—breast cancer	0.000331	0.0017	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC2A1—breast cancer	0.000327	0.00168	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ATP7B—breast cancer	0.000327	0.00168	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—NCOA1—breast cancer	0.000322	0.00165	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—breast cancer	0.000315	0.00161	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—PLG—breast cancer	0.000314	0.00161	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC2A1—breast cancer	0.000304	0.00156	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ABCC1—breast cancer	0.000304	0.00156	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ATP7B—breast cancer	0.000303	0.00156	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—HMOX1—breast cancer	0.000289	0.00149	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ABCC1—breast cancer	0.000282	0.00145	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ABCB1—breast cancer	0.000278	0.00143	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—TUBB3—breast cancer	0.000258	0.00133	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—TUBB3—breast cancer	0.00024	0.00123	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC2A2—breast cancer	0.000215	0.0011	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ABCG2—breast cancer	0.00021	0.00108	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC2A2—breast cancer	0.000199	0.00102	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ABCG2—breast cancer	0.000195	0.001	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—TFRC—breast cancer	0.000188	0.000963	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—NCOA2—breast cancer	0.000181	0.000927	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—TFRC—breast cancer	0.000174	0.000894	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ALB—breast cancer	0.000174	0.000892	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC5A5—breast cancer	0.000172	0.000884	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—NCOA2—breast cancer	0.000168	0.00086	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC2A1—breast cancer	0.000166	0.000854	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—ALB—breast cancer	0.000162	0.00083	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC5A5—breast cancer	0.00016	0.000821	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—RAF1—breast cancer	0.000157	0.000806	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC2A1—breast cancer	0.000154	0.000792	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—NCOA1—breast cancer	0.000152	0.000781	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—ALB—breast cancer	0.00015	0.00077	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—PLG—breast cancer	0.000148	0.000761	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—NCOA1—breast cancer	0.000141	0.000725	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—PLG—breast cancer	0.000138	0.000706	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—HMOX1—breast cancer	0.000137	0.000702	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ABCB1—breast cancer	0.000131	0.000674	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—HMOX1—breast cancer	0.000127	0.000652	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ABCB1—breast cancer	0.000122	0.000626	CbGpPWpGaD
Valganciclovir—Malnutrition—Methotrexate—breast cancer	0.000117	0.000164	CcSEcCtD
Valganciclovir—Haemoglobin—Doxorubicin—breast cancer	0.000117	0.000164	CcSEcCtD
Valganciclovir—Headache—Gemcitabine—breast cancer	0.000117	0.000164	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Capecitabine—breast cancer	0.000117	0.000164	CcSEcCtD
Valganciclovir—Cardiac disorder—Epirubicin—breast cancer	0.000117	0.000164	CcSEcCtD
Valganciclovir—Vomiting—Fluorouracil—breast cancer	0.000117	0.000164	CcSEcCtD
Valganciclovir—Dyspepsia—Docetaxel—breast cancer	0.000117	0.000164	CcSEcCtD
Valganciclovir—Haemorrhage—Doxorubicin—breast cancer	0.000116	0.000163	CcSEcCtD
Valganciclovir—Hepatitis—Doxorubicin—breast cancer	0.000116	0.000163	CcSEcCtD
Valganciclovir—Insomnia—Capecitabine—breast cancer	0.000116	0.000163	CcSEcCtD
Valganciclovir—Dermatitis—Fluorouracil—breast cancer	0.000116	0.000162	CcSEcCtD
Valganciclovir—Pharyngitis—Doxorubicin—breast cancer	0.000116	0.000162	CcSEcCtD
Valganciclovir—Paraesthesia—Capecitabine—breast cancer	0.000115	0.000162	CcSEcCtD
Valganciclovir—Decreased appetite—Docetaxel—breast cancer	0.000115	0.000162	CcSEcCtD
Valganciclovir—Hypersensitivity—Paclitaxel—breast cancer	0.000115	0.000162	CcSEcCtD
Valganciclovir—Headache—Fluorouracil—breast cancer	0.000115	0.000161	CcSEcCtD
Valganciclovir—Urinary tract disorder—Doxorubicin—breast cancer	0.000115	0.000161	CcSEcCtD
Valganciclovir—Oedema peripheral—Doxorubicin—breast cancer	0.000115	0.000161	CcSEcCtD
Valganciclovir—Dysgeusia—Methotrexate—breast cancer	0.000115	0.000161	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Docetaxel—breast cancer	0.000114	0.00016	CcSEcCtD
Valganciclovir—Connective tissue disorder—Doxorubicin—breast cancer	0.000114	0.00016	CcSEcCtD
Valganciclovir—Dyspnoea—Capecitabine—breast cancer	0.000114	0.00016	CcSEcCtD
Valganciclovir—Fatigue—Docetaxel—breast cancer	0.000114	0.00016	CcSEcCtD
Valganciclovir—Angiopathy—Epirubicin—breast cancer	0.000114	0.00016	CcSEcCtD
Valganciclovir—Urethral disorder—Doxorubicin—breast cancer	0.000114	0.00016	CcSEcCtD
Valganciclovir—Nausea—Mitoxantrone—breast cancer	0.000114	0.00016	CcSEcCtD
Valganciclovir—Nausea—Irinotecan—breast cancer	0.000114	0.00016	CcSEcCtD
Valganciclovir—Immune system disorder—Epirubicin—breast cancer	0.000114	0.000159	CcSEcCtD
Valganciclovir—Mediastinal disorder—Epirubicin—breast cancer	0.000113	0.000159	CcSEcCtD
Valganciclovir—Constipation—Docetaxel—breast cancer	0.000113	0.000159	CcSEcCtD
Valganciclovir—Pain—Docetaxel—breast cancer	0.000113	0.000159	CcSEcCtD
Valganciclovir—Back pain—Methotrexate—breast cancer	0.000113	0.000159	CcSEcCtD
Valganciclovir—Dyspepsia—Capecitabine—breast cancer	0.000113	0.000158	CcSEcCtD
Valganciclovir—Chills—Epirubicin—breast cancer	0.000113	0.000158	CcSEcCtD
Valganciclovir—Arrhythmia—Epirubicin—breast cancer	0.000112	0.000158	CcSEcCtD
Valganciclovir—Visual impairment—Doxorubicin—breast cancer	0.000112	0.000157	CcSEcCtD
Valganciclovir—Asthenia—Paclitaxel—breast cancer	0.000112	0.000157	CcSEcCtD
Valganciclovir—Decreased appetite—Capecitabine—breast cancer	0.000112	0.000156	CcSEcCtD
Valganciclovir—Alopecia—Epirubicin—breast cancer	0.000111	0.000156	CcSEcCtD
Valganciclovir—Nausea—Gemcitabine—breast cancer	0.000111	0.000156	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Capecitabine—breast cancer	0.000111	0.000155	CcSEcCtD
Valganciclovir—Fatigue—Capecitabine—breast cancer	0.000111	0.000155	CcSEcCtD
Valganciclovir—Pruritus—Paclitaxel—breast cancer	0.000111	0.000155	CcSEcCtD
Valganciclovir—Vision blurred—Methotrexate—breast cancer	0.00011	0.000155	CcSEcCtD
Valganciclovir—Mental disorder—Epirubicin—breast cancer	0.00011	0.000155	CcSEcCtD
Valganciclovir—Pain—Capecitabine—breast cancer	0.00011	0.000154	CcSEcCtD
Valganciclovir—Constipation—Capecitabine—breast cancer	0.00011	0.000154	CcSEcCtD
Valganciclovir—Malnutrition—Epirubicin—breast cancer	0.00011	0.000154	CcSEcCtD
Valganciclovir—Feeling abnormal—Docetaxel—breast cancer	0.000109	0.000153	CcSEcCtD
Valganciclovir—Nausea—Fluorouracil—breast cancer	0.000109	0.000153	CcSEcCtD
Valganciclovir—Eye disorder—Doxorubicin—breast cancer	0.000109	0.000153	CcSEcCtD
Valganciclovir—Ill-defined disorder—Methotrexate—breast cancer	0.000109	0.000152	CcSEcCtD
Valganciclovir—Tinnitus—Doxorubicin—breast cancer	0.000109	0.000152	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Docetaxel—breast cancer	0.000108	0.000152	CcSEcCtD
Valganciclovir—Anaemia—Methotrexate—breast cancer	0.000108	0.000152	CcSEcCtD
Valganciclovir—Cardiac disorder—Doxorubicin—breast cancer	0.000108	0.000152	CcSEcCtD
Valganciclovir—Flatulence—Epirubicin—breast cancer	0.000108	0.000151	CcSEcCtD
Valganciclovir—Tension—Epirubicin—breast cancer	0.000107	0.000151	CcSEcCtD
Valganciclovir—Dysgeusia—Epirubicin—breast cancer	0.000107	0.00015	CcSEcCtD
Valganciclovir—Diarrhoea—Paclitaxel—breast cancer	0.000107	0.00015	CcSEcCtD
Valganciclovir—Nervousness—Epirubicin—breast cancer	0.000106	0.000149	CcSEcCtD
Valganciclovir—Back pain—Epirubicin—breast cancer	0.000106	0.000149	CcSEcCtD
Valganciclovir—Feeling abnormal—Capecitabine—breast cancer	0.000106	0.000148	CcSEcCtD
Valganciclovir—Angiopathy—Doxorubicin—breast cancer	0.000106	0.000148	CcSEcCtD
Valganciclovir—Malaise—Methotrexate—breast cancer	0.000106	0.000148	CcSEcCtD
Valganciclovir—Muscle spasms—Epirubicin—breast cancer	0.000105	0.000148	CcSEcCtD
Valganciclovir—Immune system disorder—Doxorubicin—breast cancer	0.000105	0.000147	CcSEcCtD
Valganciclovir—Vertigo—Methotrexate—breast cancer	0.000105	0.000147	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Capecitabine—breast cancer	0.000105	0.000147	CcSEcCtD
Valganciclovir—Mediastinal disorder—Doxorubicin—breast cancer	0.000105	0.000147	CcSEcCtD
Valganciclovir—Body temperature increased—Docetaxel—breast cancer	0.000105	0.000147	CcSEcCtD
Valganciclovir—Abdominal pain—Docetaxel—breast cancer	0.000105	0.000147	CcSEcCtD
Valganciclovir—Leukopenia—Methotrexate—breast cancer	0.000105	0.000147	CcSEcCtD
Valganciclovir—Chills—Doxorubicin—breast cancer	0.000104	0.000147	CcSEcCtD
Valganciclovir—Arrhythmia—Doxorubicin—breast cancer	0.000104	0.000146	CcSEcCtD
Valganciclovir—Dizziness—Paclitaxel—breast cancer	0.000103	0.000145	CcSEcCtD
Valganciclovir—Vision blurred—Epirubicin—breast cancer	0.000103	0.000145	CcSEcCtD
Valganciclovir—Alopecia—Doxorubicin—breast cancer	0.000103	0.000144	CcSEcCtD
Valganciclovir—Cough—Methotrexate—breast cancer	0.000102	0.000143	CcSEcCtD
Valganciclovir—Mental disorder—Doxorubicin—breast cancer	0.000102	0.000143	CcSEcCtD
Valganciclovir—Urticaria—Capecitabine—breast cancer	0.000102	0.000143	CcSEcCtD
Valganciclovir—Ill-defined disorder—Epirubicin—breast cancer	0.000102	0.000143	CcSEcCtD
Valganciclovir—Abdominal pain—Capecitabine—breast cancer	0.000101	0.000142	CcSEcCtD
Valganciclovir—Body temperature increased—Capecitabine—breast cancer	0.000101	0.000142	CcSEcCtD
Valganciclovir—Convulsion—Methotrexate—breast cancer	0.000101	0.000142	CcSEcCtD
Valganciclovir—Malnutrition—Doxorubicin—breast cancer	0.000101	0.000142	CcSEcCtD
Valganciclovir—Anaemia—Epirubicin—breast cancer	0.000101	0.000142	CcSEcCtD
Valganciclovir—Agitation—Epirubicin—breast cancer	0.000101	0.000141	CcSEcCtD
Valganciclovir—Flatulence—Doxorubicin—breast cancer	9.99e-05	0.00014	CcSEcCtD
Valganciclovir—Arthralgia—Methotrexate—breast cancer	9.96e-05	0.00014	CcSEcCtD
Valganciclovir—Tension—Doxorubicin—breast cancer	9.94e-05	0.000139	CcSEcCtD
Valganciclovir—Vomiting—Paclitaxel—breast cancer	9.94e-05	0.000139	CcSEcCtD
Valganciclovir—Dysgeusia—Doxorubicin—breast cancer	9.92e-05	0.000139	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	9.89e-05	0.000139	CcSEcCtD
Valganciclovir—Malaise—Epirubicin—breast cancer	9.88e-05	0.000139	CcSEcCtD
Valganciclovir—Dermatitis—Paclitaxel—breast cancer	9.85e-05	0.000138	CcSEcCtD
Valganciclovir—Discomfort—Methotrexate—breast cancer	9.84e-05	0.000138	CcSEcCtD
Valganciclovir—Nervousness—Doxorubicin—breast cancer	9.84e-05	0.000138	CcSEcCtD
Valganciclovir—Vertigo—Epirubicin—breast cancer	9.84e-05	0.000138	CcSEcCtD
Valganciclovir—Leukopenia—Epirubicin—breast cancer	9.8e-05	0.000138	CcSEcCtD
Valganciclovir—Back pain—Doxorubicin—breast cancer	9.8e-05	0.000138	CcSEcCtD
Valganciclovir—Headache—Paclitaxel—breast cancer	9.79e-05	0.000137	CcSEcCtD
Valganciclovir—Hypersensitivity—Docetaxel—breast cancer	9.76e-05	0.000137	CcSEcCtD
Valganciclovir—Muscle spasms—Doxorubicin—breast cancer	9.74e-05	0.000137	CcSEcCtD
Valganciclovir—Confusional state—Methotrexate—breast cancer	9.63e-05	0.000135	CcSEcCtD
Valganciclovir—Cough—Epirubicin—breast cancer	9.56e-05	0.000134	CcSEcCtD
Valganciclovir—Anaphylactic shock—Methotrexate—breast cancer	9.55e-05	0.000134	CcSEcCtD
Valganciclovir—Vision blurred—Doxorubicin—breast cancer	9.55e-05	0.000134	CcSEcCtD
Valganciclovir—Asthenia—Docetaxel—breast cancer	9.51e-05	0.000133	CcSEcCtD
Valganciclovir—Convulsion—Epirubicin—breast cancer	9.49e-05	0.000133	CcSEcCtD
Valganciclovir—Infection—Methotrexate—breast cancer	9.49e-05	0.000133	CcSEcCtD
Valganciclovir—Hypertension—Epirubicin—breast cancer	9.46e-05	0.000133	CcSEcCtD
Valganciclovir—Hypersensitivity—Capecitabine—breast cancer	9.45e-05	0.000133	CcSEcCtD
Valganciclovir—Ill-defined disorder—Doxorubicin—breast cancer	9.4e-05	0.000132	CcSEcCtD
Valganciclovir—Pruritus—Docetaxel—breast cancer	9.38e-05	0.000132	CcSEcCtD
Valganciclovir—Nervous system disorder—Methotrexate—breast cancer	9.37e-05	0.000131	CcSEcCtD
Valganciclovir—Anaemia—Doxorubicin—breast cancer	9.37e-05	0.000131	CcSEcCtD
Valganciclovir—Thrombocytopenia—Methotrexate—breast cancer	9.35e-05	0.000131	CcSEcCtD
Valganciclovir—Arthralgia—Epirubicin—breast cancer	9.32e-05	0.000131	CcSEcCtD
Valganciclovir—Agitation—Doxorubicin—breast cancer	9.31e-05	0.000131	CcSEcCtD
Valganciclovir—Anxiety—Epirubicin—breast cancer	9.29e-05	0.00013	CcSEcCtD
Valganciclovir—Nausea—Paclitaxel—breast cancer	9.29e-05	0.00013	CcSEcCtD
Valganciclovir—Skin disorder—Methotrexate—breast cancer	9.28e-05	0.00013	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	9.26e-05	0.00013	CcSEcCtD
Valganciclovir—Hyperhidrosis—Methotrexate—breast cancer	9.23e-05	0.00013	CcSEcCtD
Valganciclovir—Discomfort—Epirubicin—breast cancer	9.21e-05	0.000129	CcSEcCtD
Valganciclovir—Asthenia—Capecitabine—breast cancer	9.21e-05	0.000129	CcSEcCtD
Valganciclovir—Malaise—Doxorubicin—breast cancer	9.14e-05	0.000128	CcSEcCtD
Valganciclovir—Dry mouth—Epirubicin—breast cancer	9.12e-05	0.000128	CcSEcCtD
Valganciclovir—Vertigo—Doxorubicin—breast cancer	9.1e-05	0.000128	CcSEcCtD
Valganciclovir—Anorexia—Methotrexate—breast cancer	9.1e-05	0.000128	CcSEcCtD
Valganciclovir—Pruritus—Capecitabine—breast cancer	9.08e-05	0.000127	CcSEcCtD
Valganciclovir—Leukopenia—Doxorubicin—breast cancer	9.07e-05	0.000127	CcSEcCtD
Valganciclovir—Diarrhoea—Docetaxel—breast cancer	9.07e-05	0.000127	CcSEcCtD
Valganciclovir—Confusional state—Epirubicin—breast cancer	9.01e-05	0.000126	CcSEcCtD
Valganciclovir—Anaphylactic shock—Epirubicin—breast cancer	8.94e-05	0.000125	CcSEcCtD
Valganciclovir—Oedema—Epirubicin—breast cancer	8.94e-05	0.000125	CcSEcCtD
Valganciclovir—Hypotension—Methotrexate—breast cancer	8.92e-05	0.000125	CcSEcCtD
Valganciclovir—Infection—Epirubicin—breast cancer	8.88e-05	0.000125	CcSEcCtD
Valganciclovir—Cough—Doxorubicin—breast cancer	8.84e-05	0.000124	CcSEcCtD
Valganciclovir—Convulsion—Doxorubicin—breast cancer	8.78e-05	0.000123	CcSEcCtD
Valganciclovir—Diarrhoea—Capecitabine—breast cancer	8.78e-05	0.000123	CcSEcCtD
Valganciclovir—Nervous system disorder—Epirubicin—breast cancer	8.77e-05	0.000123	CcSEcCtD
Valganciclovir—Dizziness—Docetaxel—breast cancer	8.76e-05	0.000123	CcSEcCtD
Valganciclovir—Thrombocytopenia—Epirubicin—breast cancer	8.75e-05	0.000123	CcSEcCtD
Valganciclovir—Hypertension—Doxorubicin—breast cancer	8.75e-05	0.000123	CcSEcCtD
Valganciclovir—Tachycardia—Epirubicin—breast cancer	8.72e-05	0.000122	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Methotrexate—breast cancer	8.7e-05	0.000122	CcSEcCtD
Valganciclovir—Skin disorder—Epirubicin—breast cancer	8.68e-05	0.000122	CcSEcCtD
Valganciclovir—Hyperhidrosis—Epirubicin—breast cancer	8.64e-05	0.000121	CcSEcCtD
Valganciclovir—Insomnia—Methotrexate—breast cancer	8.64e-05	0.000121	CcSEcCtD
Valganciclovir—Arthralgia—Doxorubicin—breast cancer	8.63e-05	0.000121	CcSEcCtD
Valganciclovir—Anxiety—Doxorubicin—breast cancer	8.6e-05	0.000121	CcSEcCtD
Valganciclovir—Paraesthesia—Methotrexate—breast cancer	8.58e-05	0.00012	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	8.57e-05	0.00012	CcSEcCtD
Valganciclovir—Discomfort—Doxorubicin—breast cancer	8.52e-05	0.00012	CcSEcCtD
Valganciclovir—Anorexia—Epirubicin—breast cancer	8.52e-05	0.00012	CcSEcCtD
Valganciclovir—Dyspnoea—Methotrexate—breast cancer	8.52e-05	0.000119	CcSEcCtD
Valganciclovir—Somnolence—Methotrexate—breast cancer	8.49e-05	0.000119	CcSEcCtD
Valganciclovir—Dizziness—Capecitabine—breast cancer	8.48e-05	0.000119	CcSEcCtD
Valganciclovir—Dry mouth—Doxorubicin—breast cancer	8.44e-05	0.000118	CcSEcCtD
Valganciclovir—Vomiting—Docetaxel—breast cancer	8.43e-05	0.000118	CcSEcCtD
Valganciclovir—Dyspepsia—Methotrexate—breast cancer	8.41e-05	0.000118	CcSEcCtD
Valganciclovir—Hypotension—Epirubicin—breast cancer	8.35e-05	0.000117	CcSEcCtD
Valganciclovir—Dermatitis—Docetaxel—breast cancer	8.35e-05	0.000117	CcSEcCtD
Valganciclovir—Confusional state—Doxorubicin—breast cancer	8.34e-05	0.000117	CcSEcCtD
Valganciclovir—Decreased appetite—Methotrexate—breast cancer	8.3e-05	0.000116	CcSEcCtD
Valganciclovir—Headache—Docetaxel—breast cancer	8.3e-05	0.000116	CcSEcCtD
Valganciclovir—Anaphylactic shock—Doxorubicin—breast cancer	8.27e-05	0.000116	CcSEcCtD
Valganciclovir—Oedema—Doxorubicin—breast cancer	8.27e-05	0.000116	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Methotrexate—breast cancer	8.25e-05	0.000116	CcSEcCtD
Valganciclovir—Fatigue—Methotrexate—breast cancer	8.23e-05	0.000116	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ALB—breast cancer	8.22e-05	0.000422	CbGpPWpGaD
Valganciclovir—Infection—Doxorubicin—breast cancer	8.22e-05	0.000115	CcSEcCtD
Valganciclovir—Pain—Methotrexate—breast cancer	8.17e-05	0.000115	CcSEcCtD
Valganciclovir—Vomiting—Capecitabine—breast cancer	8.16e-05	0.000114	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Epirubicin—breast cancer	8.14e-05	0.000114	CcSEcCtD
Valganciclovir—Nervous system disorder—Doxorubicin—breast cancer	8.11e-05	0.000114	CcSEcCtD
Valganciclovir—Thrombocytopenia—Doxorubicin—breast cancer	8.1e-05	0.000114	CcSEcCtD
Valganciclovir—Insomnia—Epirubicin—breast cancer	8.08e-05	0.000113	CcSEcCtD
Valganciclovir—Dermatitis—Capecitabine—breast cancer	8.08e-05	0.000113	CcSEcCtD
Valganciclovir—Tachycardia—Doxorubicin—breast cancer	8.07e-05	0.000113	CcSEcCtD
Valganciclovir—Headache—Capecitabine—breast cancer	8.04e-05	0.000113	CcSEcCtD
Valganciclovir—Skin disorder—Doxorubicin—breast cancer	8.03e-05	0.000113	CcSEcCtD
Valganciclovir—Paraesthesia—Epirubicin—breast cancer	8.03e-05	0.000113	CcSEcCtD
Valganciclovir—Hyperhidrosis—Doxorubicin—breast cancer	8e-05	0.000112	CcSEcCtD
Valganciclovir—Dyspnoea—Epirubicin—breast cancer	7.97e-05	0.000112	CcSEcCtD
Valganciclovir—Somnolence—Epirubicin—breast cancer	7.95e-05	0.000111	CcSEcCtD
Valganciclovir—Anorexia—Doxorubicin—breast cancer	7.88e-05	0.000111	CcSEcCtD
Valganciclovir—Nausea—Docetaxel—breast cancer	7.87e-05	0.00011	CcSEcCtD
Valganciclovir—Feeling abnormal—Methotrexate—breast cancer	7.87e-05	0.00011	CcSEcCtD
Valganciclovir—Dyspepsia—Epirubicin—breast cancer	7.87e-05	0.00011	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Methotrexate—breast cancer	7.81e-05	0.00011	CcSEcCtD
Valganciclovir—Decreased appetite—Epirubicin—breast cancer	7.77e-05	0.000109	CcSEcCtD
Valganciclovir—Hypotension—Doxorubicin—breast cancer	7.73e-05	0.000108	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Epirubicin—breast cancer	7.72e-05	0.000108	CcSEcCtD
Valganciclovir—Fatigue—Epirubicin—breast cancer	7.71e-05	0.000108	CcSEcCtD
Valganciclovir—Pain—Epirubicin—breast cancer	7.64e-05	0.000107	CcSEcCtD
Valganciclovir—Constipation—Epirubicin—breast cancer	7.64e-05	0.000107	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ALB—breast cancer	7.63e-05	0.000391	CbGpPWpGaD
Valganciclovir—Nausea—Capecitabine—breast cancer	7.62e-05	0.000107	CcSEcCtD
Valganciclovir—Urticaria—Methotrexate—breast cancer	7.59e-05	0.000106	CcSEcCtD
Valganciclovir—Body temperature increased—Methotrexate—breast cancer	7.55e-05	0.000106	CcSEcCtD
Valganciclovir—Abdominal pain—Methotrexate—breast cancer	7.55e-05	0.000106	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Doxorubicin—breast cancer	7.54e-05	0.000106	CcSEcCtD
Valganciclovir—Insomnia—Doxorubicin—breast cancer	7.48e-05	0.000105	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—RAF1—breast cancer	7.43e-05	0.000381	CbGpPWpGaD
Valganciclovir—Paraesthesia—Doxorubicin—breast cancer	7.43e-05	0.000104	CcSEcCtD
Valganciclovir—Dyspnoea—Doxorubicin—breast cancer	7.37e-05	0.000103	CcSEcCtD
Valganciclovir—Feeling abnormal—Epirubicin—breast cancer	7.37e-05	0.000103	CcSEcCtD
Valganciclovir—Somnolence—Doxorubicin—breast cancer	7.35e-05	0.000103	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Epirubicin—breast cancer	7.31e-05	0.000103	CcSEcCtD
Valganciclovir—Dyspepsia—Doxorubicin—breast cancer	7.28e-05	0.000102	CcSEcCtD
Valganciclovir—Decreased appetite—Doxorubicin—breast cancer	7.19e-05	0.000101	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Doxorubicin—breast cancer	7.14e-05	0.0001	CcSEcCtD
Valganciclovir—Fatigue—Doxorubicin—breast cancer	7.13e-05	0.0001	CcSEcCtD
Valganciclovir—Urticaria—Epirubicin—breast cancer	7.1e-05	9.96e-05	CcSEcCtD
Valganciclovir—Pain—Doxorubicin—breast cancer	7.07e-05	9.92e-05	CcSEcCtD
Valganciclovir—Constipation—Doxorubicin—breast cancer	7.07e-05	9.92e-05	CcSEcCtD
Valganciclovir—Body temperature increased—Epirubicin—breast cancer	7.07e-05	9.91e-05	CcSEcCtD
Valganciclovir—Abdominal pain—Epirubicin—breast cancer	7.07e-05	9.91e-05	CcSEcCtD
Valganciclovir—Hypersensitivity—Methotrexate—breast cancer	7.04e-05	9.87e-05	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—RAF1—breast cancer	6.9e-05	0.000354	CbGpPWpGaD
Valganciclovir—Asthenia—Methotrexate—breast cancer	6.85e-05	9.61e-05	CcSEcCtD
Valganciclovir—Feeling abnormal—Doxorubicin—breast cancer	6.82e-05	9.56e-05	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Doxorubicin—breast cancer	6.76e-05	9.49e-05	CcSEcCtD
Valganciclovir—Pruritus—Methotrexate—breast cancer	6.76e-05	9.48e-05	CcSEcCtD
Valganciclovir—Hypersensitivity—Epirubicin—breast cancer	6.59e-05	9.24e-05	CcSEcCtD
Valganciclovir—Urticaria—Doxorubicin—breast cancer	6.57e-05	9.22e-05	CcSEcCtD
Valganciclovir—Abdominal pain—Doxorubicin—breast cancer	6.54e-05	9.17e-05	CcSEcCtD
Valganciclovir—Body temperature increased—Doxorubicin—breast cancer	6.54e-05	9.17e-05	CcSEcCtD
Valganciclovir—Diarrhoea—Methotrexate—breast cancer	6.54e-05	9.17e-05	CcSEcCtD
Valganciclovir—Asthenia—Epirubicin—breast cancer	6.41e-05	9e-05	CcSEcCtD
Valganciclovir—Pruritus—Epirubicin—breast cancer	6.32e-05	8.87e-05	CcSEcCtD
Valganciclovir—Dizziness—Methotrexate—breast cancer	6.32e-05	8.86e-05	CcSEcCtD
Valganciclovir—Diarrhoea—Epirubicin—breast cancer	6.12e-05	8.58e-05	CcSEcCtD
Valganciclovir—Hypersensitivity—Doxorubicin—breast cancer	6.09e-05	8.55e-05	CcSEcCtD
Valganciclovir—Vomiting—Methotrexate—breast cancer	6.07e-05	8.52e-05	CcSEcCtD
Valganciclovir—Dermatitis—Methotrexate—breast cancer	6.02e-05	8.44e-05	CcSEcCtD
Valganciclovir—Headache—Methotrexate—breast cancer	5.98e-05	8.39e-05	CcSEcCtD
Valganciclovir—Asthenia—Doxorubicin—breast cancer	5.93e-05	8.32e-05	CcSEcCtD
Valganciclovir—Dizziness—Epirubicin—breast cancer	5.91e-05	8.29e-05	CcSEcCtD
Valganciclovir—Pruritus—Doxorubicin—breast cancer	5.85e-05	8.21e-05	CcSEcCtD
Valganciclovir—Vomiting—Epirubicin—breast cancer	5.68e-05	7.97e-05	CcSEcCtD
Valganciclovir—Nausea—Methotrexate—breast cancer	5.67e-05	7.96e-05	CcSEcCtD
Valganciclovir—Diarrhoea—Doxorubicin—breast cancer	5.66e-05	7.94e-05	CcSEcCtD
Valganciclovir—Dermatitis—Epirubicin—breast cancer	5.63e-05	7.9e-05	CcSEcCtD
Valganciclovir—Headache—Epirubicin—breast cancer	5.6e-05	7.85e-05	CcSEcCtD
Valganciclovir—Dizziness—Doxorubicin—breast cancer	5.47e-05	7.67e-05	CcSEcCtD
Valganciclovir—Nausea—Epirubicin—breast cancer	5.31e-05	7.45e-05	CcSEcCtD
Valganciclovir—Vomiting—Doxorubicin—breast cancer	5.26e-05	7.38e-05	CcSEcCtD
Valganciclovir—Dermatitis—Doxorubicin—breast cancer	5.21e-05	7.31e-05	CcSEcCtD
Valganciclovir—Headache—Doxorubicin—breast cancer	5.18e-05	7.27e-05	CcSEcCtD
Valganciclovir—Nausea—Doxorubicin—breast cancer	4.91e-05	6.89e-05	CcSEcCtD
